<DOC>
	<DOCNO>NCT00739648</DOCNO>
	<brief_summary>Patients Chronic Obstructive Pulmonary Disease ( COPD ) suffer frequent recurrent acute exacerbation ( AECB ) associate enormous healthcare expenditures significant morbidity , specifically increase risk death , decline pulmonary function significant change quality life . Bacteria appear important role acute exacerbation chronic bronchitis COPD . Studies acute exacerbation COPD show reduction bacterial load prolong exacerbation-free interval . In addition , recent study indicate acquisition new strain H. influenzae , M. catarrhalis , S. pneumoniae P. aeruginosa responsible many exacerbation . Chronic inflammation bacterial infection predispose many patient frequent recurrent acute exacerbation . Mpex believe intermittent administration inhale MP-376 high risk patient decrease incidence acute exacerbation lower organism burden , resultant inflammation , well pre-emptive eradication newly acquire bacterial strain .</brief_summary>
	<brief_title>A Phase 2 Study MP-376 Prevent Acute Exacerbations Chronic Obstructive Pulmonary Disease ( COPD ) Patients</brief_title>
	<detailed_description>This study Phase 2 , multi-center , randomize , double-blind , placebo-controlled study evaluate safety , tolerability , efficacy MP-376 inhalation solution give daily 5 day 28 day treatment cycle COPD patient .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<criteria>Inclusion Criteria ( select ) : &gt; 40 year age History COPD Forced expiratory volume 1 second ( FEV1 ) &lt; /= 70 % predict FEV1/Forced vital capacity ( FVC ) &lt; /= 0.7 value screen Have least two acute exacerbation episode proceed year Clinically stable change health status within last 30 day Lifetime smoke history least 10 packyears Willing able use daily electronic diary Exclusion Criteria ( select ) : Use systemic inhaled antibiotic within 30 day prior baseline History hypersensitivity fluoroquinolones intolerance aerosol medication Creatinine clearance &lt; 40 mg/ml/min , AST , ALT &gt; /= 5 x upper limit normal ( ULN ) total bilirubin &gt; /= 3 x ULN Screening</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>COPD</keyword>
	<keyword>Patients</keyword>
</DOC>